Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis by unknown
FLUIDS AND BARRIERS
OF THE CNS
Pishko et al. Fluids and Barriers of the CNS 2015, 12:5
http://www.fluidsbarrierscns.com/content/12/1/5RESEARCH Open AccessVascular endothelial growth factor blockade
alters magnetic resonance imaging biomarkers
of vascular function and decreases barrier
permeability in a rat model of lung cancer
brain metastasis
Gregory L Pishko1, Leslie L Muldoon1, Michael A Pagel3, Daniel L Schwartz1 and Edward A Neuwelt1,2,3*Abstract
Background: Blockade of vascular endothelial growth factor (VEGF) to promote vascular normalization and inhibit
angiogenesis has been proposed for the treatment of brain metastases; however, vascular normalization has not
been well-characterized in this disease. We investigated the effect of treatment with bevacizumab anti-VEGF
antibody on magnetic resonance imaging (MRI) biomarkers of brain tumor vascular characteristics in comparison to
small molecule delivery in a rat model of human lung cancer brain metastasis.
Methods: Athymic rats with A549 human lung adenocarcinoma intracerebral xenografts underwent MRI at 11.75 T
before and one day after treatment with bevacizumab (n = 8) or saline control (n = 8) to evaluate tumor
volume, free water content (edema), blood volume and vascular permeability (Ktrans). One day later, permeability
to 14C-aminoisobutyric acid (AIB) was measured in tumor and brain to assess the penetration of a small drug-like
molecule.
Results: In saline control animals, tumor volume, edema and permeability increased over the two day assessment
period. Compared to controls, bevacizumab treatment slowed the rate of tumor growth (P = 0.003) and blocked the
increase in edema (P = 0.033), but did not alter tumor blood volume. Bevacizumab also significantly reduced Ktrans
(P = 0.033) and AIB passive permeability in tumor (P = 0.04), but not to peritumoral tissue or normal brain. Post-treatment
Ktrans correlated with AIB levels in the bevacizumab-treated rats but not in the saline controls.
Conclusions: The correlation of an MRI biomarker for decreased vascular permeability with decreased AIB concentration
in tumor after antiangiogenic treatment suggests that bevacizumab partially restored the normal low permeability
characteristics of the blood–brain barrier in a model of human lung cancer brain metastasis.
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Brain metastasis occurs in 15–20% of patients with non-
small cell lung cancer (NSCLC), resulting in high mor-
bidity and rapid mortality [1]. Current treatments for
brain metastases include surgery, whole brain irradi-
ation, and stereotactic radiosurgery [2]. Chemotherapy
regimens can show efficacy in brain metastases but typ-
ically are less effective than in the systemic mass, at least
in part because drug delivery is limited by malformed
neovasculature and inconsistent permeability of the
blood–brain barrier (BBB) and blood-tumor barrier
(BTB) [3]. Treatments for lung cancer brain metastases
have only short-term efficacy, and after recurrence there
is no standard second-line regimen that offers consistent
benefit.
Vascular endothelial growth factor (VEGF) is highly
expressed in many human brain tumors [4], where it
promotes tumor angiogenesis, providing critical support
for tumor growth and survival [5,6]. Bevacizumab is an
anti-VEGF-A monoclonal antibody that inhibits angio-
genesis and also promotes vascular normalization by
pruning immature vessels and improving perivascular
cell and basement membrane coverage and function [7].
As a salvage therapy in progressive malignant glioblast-
oma, bevacizumab decreases tumor growth and reduces
edema and steroid use [8,9], but recent reports indicate
no survival benefit in newly diagnosed glioblastoma [10].
In NSCLC brain metastases, bevacizumab has been pro-
posed as both front-line treatment and as salvage ther-
apy in combination with chemotherapy [11-13].
Magnetic resonance imaging (MRI) techniques provide
a non-invasive mechanism to assess tumor vasculature
and the effects of bevacizumab over time [14]. We used
MRI to measure brain tumor growth, water content
(edema) [15,16], relative cerebral blood volume (rCBV)
[17-19], and vascular permeability as determined by
the vascular transfer coefficient (Ktrans) [20,21] in a rat
model of human lung cancer brain metastasis. In contrast
to the current hypothesis that vascular normalization im-
proves chemotherapy delivery, we hypothesize that re-
stored BBB function will actually decrease drug delivery
[22]. The purpose of this study was to determine the
effects of bevacizumab on MRI biomarkers of vascular
characteristics in comparison to small molecule delivery in
brain metastases.
Methods
Tumor implantation and treatments
The care and use of animals was approved by the
Institutional Animal Care and Use Committee and was
supervised by the Oregon Health & Science University
(OHSU) Department of Comparative Medicine. The A549
human lung adenocarcinoma cells, obtained from ATCC
(American Type Culture Collection, Manassas VA, USA)and used at an early passage number, were cultured in
DME with 10% serum and penicillin, streptomycin and
gentamicin antibiotics. Adult female nude rats (200–220 g)
from the OHSU colony were anesthetized with intraperito-
neal (IP) ketamine (60 mg/kg) and diazepam (7.5 mg/kg).
Tumor cells (12 μl, ~106 cells, >90% viability) were
inoculated at stereotactic coordinates for intracerebral
localization in the right caudate putamen (vertical
bregma, −3.1 mm lateral, −6.5 mm depth). After tumors
developed to >6 mm3 (3–4 weeks) rats underwent pre-
treatment MRI and were randomized 24 h later to receive
either 1) intravenous (IV) saline (saline control group) or
2) bevacizumab (Avastin, Genentech, San Francisco,
USA, 45 mg/kg IV, n = 8 per group). Post-treatment MRI
was performed 24 h after treatment. Aminoisobutyric
acid (AIB) passive permeability was assessed 24 h after
the post-treatment MRI (48 h after bevacizumab).
Magnetic resonance imaging
Animals were anesthetized using IP ketamine (60 mg/kg
IP) and dexmedetomidine (0.6 mg/kg IP; Henry Schein
Animal Health, Dublin OH, USA), with atipamezole
(1 mg IP; Henry Schein Animal Health, Dublin OH,
USA) reversal at end of study. Warm air was circulated
through the bore of the MRI scanner to maintain a
physiological temperature. MRI was performed at 11.75 T
(Bruker Corporation, Billerica MA, USA) at the Advanced
Imaging Research Center using a Bruker volume coil for
transmitting and a Bruker surface coil for receiving. All
images were obtained in the axial plane at 1 mm slice
thickness. Prior to the injection of contrast agent, anatom-
ical images were acquired: high resolution T1-weighted
fast low-angle shot (FLASH) (TR/TE = 160.0/1.6 ms; flip
angle (FA) = 60°; matrix size = 256 × 256; slices = 25;
field of view (FOV) = 3.2 × 3.2 × 2.5 cm; number of
averages = 4; TA = 2.72 min); T2-weighted rapid acquisition
refocusing echoes (RARE) (TR/TE = 4020.6/23.6 ms;
RARE factor = 8; matrix size = 256 × 256; slices = 25;
FOV = 3.2 × 3.2 × 2.5 cm; number of averages = 1;
TA = 2.13 min); and T2*-weighted FLASH sequence
(TR/TE = 430.3/6.6 ms; FA = 30°; matrix size = 384 × 384;
slices = 25; FOV = 3.2 × 3.2 × 2.5 cm; total acquisition
time = 2.75 min).
Ferumoxytol (Feraheme, AMAG Pharmaceutical, Inc.,
Waltham MA, USA), an iron oxide nanoparticle, was de-
livered by bolus injection (30 mg/ml, 60 μL) via tail vein
catheter (3 ml/min). Pre- and post- ferumoxytol high
resolution T2*-weighted images were acquired for the
creation of steady-state ΔR2* maps.
Pre-gadolinium based contrast agent (GBCA) longitu-
dinal relaxivity (R1) values were acquired by a fast spin-
echo inversion recovery sequence (TR/TE = 9000/5.1 ms;
inversion times (TI) = 0.14/0.3/0.6/1.2/2.5/5.0/8.5 s; RARE
factor = 8; matrix size = 128 × 64; slices = 1; field of
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slice was acquired as in the ferumoxytol steady-state MRI.
A dynamic contrast-enhanced (DCE)-MRI FLASH se-
quence (TR/TE = 25.0/1.4 ms; FA = 20°; matrix = 128 × 64;
slices = 3; field of view = 4.48 × 2.24 × 0.3 cm; inter-
sampling interval = 1.6 s; repetitions = 400; number of
averages = 1; total acquisition time = 10.67 min) was used
to track extravasation and washout of low molecular
weight gadodiamide, Gd-DTPA-BMA (Omniscan, GE
Healthcare, Piscataway, NJ USA), in tumor for ~10 min.
Gd-DTPA-BMA was delivered by bolus injection
(287 mg/ml, 60 μL) via a tail vein catheter (1 ml/min). Post
Gd-DTPA-BMA T1-weighted images were acquired after
DCE-MRI.
MRI data analysis
T2-weighted images were used to identify tumor perim-
eter determined by hyperintensity compared to normal
surrounding grey matter. Total tumor volume was mea-
sured by the summation of tumor volumes in multiple
T2-weighted slices, manually outlined using ImageJ soft-
ware (NIH).
MRI-derived measurements of tumor volume, R1,
Ktrans, and rCBV were performed before and after treat-
ment and were normalized to percent change from base-
line ([post-pre]/pre). All MRI-derived measurements
were averaged over voxels within a region of interest
(ROI) matched to the central slice used to calculate
tumor volume in T2-weighted images.
Pre-GBCA R1 (R1 = 1/T1) spin–lattice relaxation rates
in the tumor were calculated by fitting MR signal to an
inversion recovery model with three fitted parameters:
R1, M0 (Boltzmann magnetization), and α (imperfect in-
version correction): S(TI) = │M0*(1 – α*exp(−TI*R1)│;
where S is the MR signal, which is a function of TI.
Vascular permeability parameters were determined
using DCE-MRI data modeled with an in-house software
(BOLERO) in MATLAB (The Mathworks, Inc., Natick,
MA, USA), using a two-compartment model [21] of
transvascular exchange between vascular and tissue
space to extract permeability as measured by the rate
transfer constant, Ktrans and extravascular-extracellular
volume fraction, ve. The area under the longitudinal
relaxivity R1 curve within the tumor is proportional to
the concentration of Gd-DTPA in tumor tissue. The
arterial input function for the model was measured as
MR signal time course of contrast agent in blood in the
sagittal sinus during the GBCA injection. The amplitude
of the clearance was adjusted for each rat based on a ref-
erence tissue (temporalis) method [19].
Blood volume was assessed using steady-state ΔR2*,
with ferumoxytol as a blood-pool contrast agent. ΔR2*
maps were created assuming that the changes in trans-
verse relaxation rate have a linear relationship withferumoxytol contrast agent concentration [23]. Steady-
state-CBV maps were created on a pixel-by-pixel basis
in MATLAB using the relationship: ΔR2* = ln(Spre/Spost)/
TE, where Spre is the signal intensity pre-ferumoxytol
and Spost is the signal intensity at a steady-state signal
intensity corresponding to a constant concentration of
ferumoxytol in blood. Relative cerebral blood volume
(rCBV) was determined by comparing tumor ΔR2* to an
equivalent ROI in contralateral normal brain.
Small molecule permeability
The day after post-treatment dynamic MRI, rats re-
ceived 12.5 μCi of 14C-AIB (MW = 103 Da; American
Radiolabeled Chemicals, St. Louis MO, USA) adminis-
tered IV for assessment of unidirectional tracer leakage
from the blood to brain tissue. A serum sample was col-
lected 10 min after AIB administration followed by perfu-
sion to clear the vasculature. The brains were harvested
and four regions were dissected: tumor mass, tissue 1–
2 mm brain around tumor (BAT), tissue 1–2 mm ipsilat-
eral brain distant to tumor (BDT), and contralateral left
hemisphere (LH) normal brain tissue. Each tissue sample
was weighed, solubilized in 2 ml of sodium hydroxide
overnight (MP Biomedicals, Solon, OH, USA) and radio-
activity was determined by liquid scintillation counting in
20 ml of CytoScint ES (MP Biomedicals, Solon, OH,
USA). Results were measured as percent injected dose
normalized to 1 g of tissue.
Statistical analysis
A Student’s 2-tailed, paired t-test was used to test statis-
tical significance of change from pre- to post-treatment
for tumor growth, R1, K
trans, ve, and steady-state rCBV.
Unpaired t-tests were used to assess changes in these pa-
rameters comparing the saline control and bevacizumab
treatment groups. Pearson’s r was used to measure the
strength of the relationship between parameters. Statis-
tical tests were performed using Microsoft Excel and
Graphpad Prism. Data within figures are presented as
mean and standard error of the mean (SEM) of the
change from baseline.
Results
To evaluate the growth of A549 human lung adenocar-
cinoma xenografts in rat brain we used standard ana-
tomical T2-weighted imaging (Figure 1). The tumors
were characterized as a single solid mass with clearly
delineated tumor borders defined between the hyperin-
tensity of the tumor and the isointensity of normal sur-
rounding brain on a central tumor-bisecting slice. Over
the two days between pre- and post-treatment MRI, the
morphology within the tumor border showed little
change, with no detected increase in necrosis. Tumor
growth was apparent in all saline control rats, with a
Figure 1 Bevacizumab slows the growth of brain metastases. The volume of intracerebral A549 human lung adenocarcinoma tumor was
determined using T2-weighted MRI. A) Representative tumors are shown for pretreatment (yellow) and post-treatment (red) in the saline
control (SAL) and bevacizumab-treated (BEV) animals. A 3-dimensional representation is shown for each tumor. The axis labels are A, anterior, L, left,
and S, superior. B) Normalized tumor growth in saline control and bevacizumab treated animals (n = 8 per group). Data are shown as mean ± standard
error of the mean change from baseline. * P = 0.003 versus the saline control group.
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pared to baseline). In the bevacizumab-treated rats,
mean tumor volume increased by 14.6 ± 5.1% compared
to baseline, although one rat showed a 5% decrease in
tumor volume. Bevacizumab significantly slowed tumor
growth compared to the saline controls (t(14) = 3.52,
P = 0.003). Pre and post-treatment tumor volumes are
shown in Table 1.
We quantified the effect of bevacizumab on pre-
gadolinium contrast agent longitudinal relaxation rate
(R1) values, which serve as an indirect measure of free
water present in tumor, and BAT (Figure 2; Table 1). R1
is inversely proportional to edema. Pre-treatment R1




Tumor volume, range (mm3) 7.34–36.9
Tumor volume, mean ± sd (mm3) 14.7 ± 9.4
R1, range (ms
–1) 0.45–0.54
R1, mean ± sd (ms
–1) 0.53 ± 0.03
Steady-state rCBV, range 0.76–2.89
Steady-state rCBV, mean ± sd 1.45 ± 0.83
Ktrans, range (min–1) 0.027–0.084
Ktrans, mean ± sd (min–1) 0.047 ± 0.018
R1: longitudinal relaxivity, rCBV: relative cerebral blood volume, K
trans: vascular transhyperintense (n = 8) tumor masses relative to contra-
lateral grey matter. Two days later, all saline control
animals had an R1 lower than contralateral brain
(−5.69 ± 2.11% mean change from baseline, paired t-test
P = 0.033) indicative of increased edema with tumor pro-
gression. In contrast, bevacizumab-treated tumors con-
tinued to show heterogeneous R1 maps (4 hyperintense,
4 hypointense). Mean R1 values increased by 1.95 ± 2.43%
after bevacizumab, which was not different from base-
line, but was significantly different from the saline
controls (t(14) = −2.37, P = 0.033). No significant differ-
ence in average R1 changes was found in temporalis
muscle or contralateral grey matter comparing treatment




22.7 ± 15.7 16.1 ± 13.2 17.8 ± 12.3
0.42–0.55 0.45–0.57 0.49–0.59
0.50 ± 0.04 0.53 ± 0.04 0.54 ± 0.04
0.63–1.63 0.92–1.61 0.63–1.55
1.17 ± 0.45 1.20 ± 0.26 0.93 ± 0.26
0.026–0.084 0.016–0.064 0.014–0.054
0.056 ± 0.018 0.043 ± 0.016 0.031 ± 0.014
fer coefficient.
Figure 2 Bevacizumab blocks the increase in edema in A549 xenografts. The longitudinal relaxation rate (R1) prior to gadolinium-based
contrast agent is inversely proportional to free water (edema). A) R1 maps in representative intracerebral A549 human lung adenocarcinoma
xenografts (right hemisphere) compared to a matched region of interest in the control left hemisphere are shown before and after
treatment with saline (SAL) or bevacizumab (BEV). B) Normalized change in R1 within the tumor region of interest in saline control and
bevacizumab-treated tumors (n = 8 per group). Data are shown as mean ± standard error of the mean change from baseline. * P= 0.033 versus saline
control group.
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ΔR2* maps to measure tumor rCBV (Figure 3; Table 1).
Mottled areas of inflated blood volume were detected
within the tumor border, but overall blood volumes were
not different from normal brain. Two pretreatment tu-
mors and no post-treatment tumors showed elevated
rCBV (Table 1). There was no change in rCBV withFigure 3 Effect of bevacizumab on tumor blood volume. Steady-state
in intracerebral A549 human lung adenocarcinoma xenografts. A) SS-rCBV
(right hemisphere, arrows) before and after saline (SAL) or bevacizumab (BEV)
SS-CBV in tumors in the saline and bevacizumab-treatment tumors (n = 8 per
from baseline.tumor growth or with bevacizumab treatment in the
A549 lung cancer xenograft model.
We investigated the vascular permeability of lung can-
cer brain metastases using DCE-MRI before and after
treatment. Two-compartment model analysis yielded
voxel-wise measurements of the rate transfer constant,
Ktrans and extravascular-extracellular volume fraction, ve.ΔR2* maps of relative cerebral blood volume (SS-rCBV) were measured
in representative animals comparing control left hemisphere and tumor
. High rCBV is seen as mottled hot spots of hyperintensity. B) Normalized
group). Data are shown as mean ± standard error of the mean change
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of the tumor on Ktrans maps, while permeability de-
creased radially towards the tumor boundary (Figure 4A).
Baseline Ktrans was not different between groups (P = 0.65)
but was inconsistent between animals, varying from 0.016
to 0.084 min–1 (Table 1). For the saline control group,
mean Ktrans increased by 34 ± 24% (Figure 4B) (P = 0.36),
but this included 3 of 8 rats in which Ktrans actually de-
creased with tumor progression (Figure 4C). Bevacizumab
resulted in a 26 ± 10% decrease in vessel permeability com-
pared to baseline (P = 0.028), which was significantly
reduced compared to the saline control (t(14) = 2.29,Figure 4 Bevacizumab decreases tumor vessel permeability. Ktrans as
contrast-enhanced MRI. A) Representative Ktrans maps of A549 intracerebr
B) Normalized change in Ktrans in the saline control and bevacizumab-trea
error of the mean change from baseline. * P < 0.05 versus saline control g
rats in the saline (black) and bevacizumab (red) groups.P = 0.04). One bevacizumab-treated rat showed increased
permeability (Figure 4C). The extravascular-extracellular
volume fraction, ve was not different between groups and
was not altered by bevacizumab treatment.
Leakage of the low molecular weight marker 14C-AIB
was measured in dissected intracerebral tumor, BAT, BDT
and contralateral left hemisphere as a surrogate for drug
delivery (Figure 5A). The saline control tumor showed
elevated AIB levels in the tumor mass (0.41 ± 0.07%
delivered dose) and in the BAT (0.13 ± 0.02% delivered
dose) compared to normal brain tissues (0.065 ± 0.005%
delivered dose; P = 0.003 and P = 0.004 respectively).a measure of vascular permeability was determined using dynamic
al xenografts before and after saline (SAL) or bevacizumab (BEV).
ted animals (n = 8 per group). Data are shown as mean ± standard
roup. C) Pretreatment and post-treatment Ktrans values in individual
Figure 5 Bevacizumab decreases AIB passive permeability.
A) The % delivered dose of 14C-AIB was measured in tumor, brain
around tumor (BAT), brain distant from tumor (BDT) and contralateral
left hemisphere (LH) in saline control and bevacizumab-treated rats
with intracerebral A549 xenografts. Bevacizumab decreased AIB
concentration in the tumor mass compared to saline control (* P= 0.04)
but the effect was not significant in other brain regions. Data
are indicated as mean ± SEM of % delivered dose. B) Correlation
of AIB concentration with Ktrans measurements of vascular permeability.
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levels in tumor (0.22 ± 0.05% delivered dose) and BAT
(0.10 ± 0.01% delivered dose) compared to normal brain
(0.064 ± 0.022; P = 0.015 and P = 0.005 respectively).
Compared with the saline control group, bevacizumab
significantly decreased AIB passive permeability to the
tumor mass (t(14) = 2.25, P = 0.04). AIB levels in BAT,
ipsilateral BDT and contralateral left hemisphere
were not affected by bevacizumab treatment. Serum
activity of 14C-AIB did not differ between saline control
and bevacizumab (0.51 ± 0.04 vs. 0.48 ± 0.03, respectively,P = 0.54), nor did AIB clearance (saline control 83.4 ± 3.0%;
bevacizumab 85.1 ± 2.7%, P = 0.68).
The post-treatment Ktrans values were significantly cor-
related with AIB tracer levels within the tumor for the
bevacizumab group (r2 = 0.80, P = 0.003, Figure 5B). In
contrast, there was no correlation between post-
treatment Ktrans and the passive permeability of 14C-AIB
in the control group (r2 = 0.04, P = 0.64).
Discussion
A recent review of the future of bevacizumab treatment
for glioblastoma [24] underscores two important themes
that are equally valid for treatment of metastases: 1) the
importance of identifying imaging markers that predict
individual response; and 2) the importance of investigat-
ing bevacizumab in combination with other therapies.
This current preclinical study sought to address these
points by acquiring quantitative MRI parameters in con-
junction with tracer passive permeability as a marker of
drug delivery in a brain metastasis model.
The primary goal for using bevacizumab as a cancer
therapeutic is to block the development of tumor neo-
vasculature in order to starve the tumor to decrease
tumor growth and/or kill existing tumor. We found that
bevacizumab significantly slowed the growth of the rap-
idly growing A549 lung cancer brain metastasis model
but overall did not induce tumor regression. Blocking
VEGF-A with bevacizumab does not affect A549 cell
proliferation in vitro [25], suggesting that the effects of
bevacizumab on tumor growth in this study were not
due to direct cytotoxicity. Antitumor efficacy of anti-
angiogenics has been demonstrated in brain metastasis
models [26,27] and in the clinical setting [11,13]. We did
not assess long term tumor growth inhibition or survival
in this study because our aim was to obtain matching
AIB permeability measurements for every animal in order
to correlate with early post-treatment MRI biomarkers.
Elevated blood volume, >1.75 compared to normal
brain, is thought to indicate actively growing tumor, at
least in high grade glioma [17,23]. We evaluated rCBV
in brain metastases using the steady-state MRI tech-
nique with ferumoxytol iron oxide nanoparticles as a
blood pool contrast agent to obtain very high resolution
blood volume maps [23]. We found mottled hot spots
of elevated rCBV, but overall blood volume was low in
the A549 model, despite the rapid growth of these tu-
mors. The low baseline rCBV in this model limited the
possibility of observing a significant effect of bevacizumab.
Previous preclinical studies have demonstrated decreased
blood volume after bevacizumab in a SCLC intracerebral
xenograft model [28] and prostate cancer brain metastases
[29], as well as glioblastoma models [17,30].
A secondary goal for using bevacizumab in GBM is to
reduce edema, but it is unclear if this mechanism will be
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significant edema and mass effects, decreasing quality of
life due to neurological deficits and headache. Cortico-
steroids are typically used to control edema in CNS ma-
lignancies, but their use is associated with a multitude of
dose- and time-dependent adverse side effects [31]. We
assessed interstitial fluid environment changes in the
tumor by measuring the pre-contrast longitudinal relax-
ation rate on quantitative MRI [15,16]. In contrast with
normal tumor progression and concomitant edema in
control animals evidenced here by a decrease in R1, the
R1 was relatively stable in bevacizumab-treated animals.
A possible explanation is that the treatment reduced the
permeability of plasma fluid from the vascular space into
the interstitial space, thereby preventing the exacerbation
of edema within the tumor. Alternatively, an increase in
tumor R1 may reflect hypocellularity and is thus a generic
biomarker of early cytotoxic response [32]. Quantitative
transverse relaxation measurements may reveal more
detailed changes in free water content [33]. Our results
support the use of bevacizumab as an effective (albeit ex-
pensive) alternative to steroid use in brain metastases.
A final rationale for the use of bevacizumab in brain
metastases is the concept of vascular normalization
[6,7]. Blocking VEGF signaling in systemic tumors pro-
duces a morphologically and functionally normalized
vasculature by pruning immature vessels and improving
perivascular cell and basement membrane coverage and
function [34]. It is hypothesized that normalization of
existing tumor vasculature will improve chemotherapy
delivery and chemotherapy/radiotherapy efficacy [7,24,34].
Brain metastases can induce neovascularization, with leaky
vessels, but can also co-opt existing brain vasculature, with
near-normal BBB, particularly in the tumor-infiltrated BAT
[35]. Clinically brain metastases can show highly variable
permeability, and this is recapitulated in hematogenous
metastases in animal models [36]. Xenograft models typic-
ally provide more uniform permeability, given similar size
and location of tumor mass. However, permeability was
highly variable in the A549 xenograft model, with nearly
one order of magnitude variability in Ktrans values among
the different tumors at baseline. Variable permeability may
reflect inconsistent neovascularization versus vessel co-
option with resulting differences in BBB dysfunction.
We hypothesize that vascular normalization with anti-
VEGF agents may restore the low permeability charac-
teristics of the BBB in brain tumors, therefore actually
decreasing drug delivery [22]. Several reports support
the concept that vascular normalization with anti-VEGF
agents may decrease BTB permeability. The VEGF re-
ceptor inhibitor vandetanib decreased temozolomide-
induced apoptosis in brain tumor models [37], while
another anti-VEGF receptor agent cediranib decreased
the permeability of the BBB in a prostate cancer brainmetastasis xenograft model [29]. In the current study,
permeability in the A549 tumor mass and tumor perim-
eter decreased following bevacizumab, which correlated
with decreased passive permeability of 14C-AIB. AIB was
chosen because it is a low molecular weight marker
(103 Da) equivalent in size to many chemotherapeutics,
and because it is not a substrate for the P-glycoprotein
family of drug exporters, so its concentration in tumors
is primarily a function of vascular permeability. One
limitation of the study was that the gross dissection
technique used for AIB quantification localized inhomo-
geneities that could be better detected with quantitative
autoradiography. Nevertheless, AIB levels were was
highly correlated with Ktrans after bevacizumab treat-
ment, but not in the saline controls, suggesting that
VEGF blockade did indeed induce BBB normalization in
this metastasis model. Given these results, it is reason-
able to expect that bevacizumab treatment may result
in decreased delivery and resultant intratumoral concen-
tration of chemotherapeutic agents whose molecular
weights are similar to AIB, thereby decreasing thera-
peutic effects. Additionally, vascular normalization may
decrease contrast leakage on MRI to give the appearance
of response to therapy, while asymptomatic tumor growth
proceeds masked by an intact BBB. This phenomenon,
known as pseudoresponse, has been documented in glio-
blastoma [38] and may also occur in brain metastases
treated with bevacizumab.
Conclusions
This study used MRI biomarkers and delivery of a low
molecular weight radioactive tracer to assess the effects
of bevacizumab on the vasculature in and around intra-
cerebral human lung cancer xenografts and the perme-
ability of the BTB to AIB after bevacizumab treatment.
Compared to saline controls, bevacizumab slowed tumor
growth, blocked the increase in edema, and significantly
decreased both tumor vessel permeability and the poten-
tial for drug delivery. These data support the efficacy of
MRI measurement to clarify the effects of vascular target-
ing agents in brain metastases, and provides compelling
evidence of bevacizumab-mediated vascular normalization.
The current study underscores the importance of deter-
mining the vascular normalization window based on such
factors as tumor type, bevacizumab dose and timing, and
initial permeability state.
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